An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study

No abstract is available for this paper.

• Publication year

  2003

• Venue

  European Journal of Heart Failure

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1388-9842(03)00044-8PMID 12921807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy.

  2002cited by this paper
• Amino Acid 49 Polymorphisms of the Human &bgr; 1 -Adrenergic Receptor Affect Agonist-Promoted Trafficking

  2002cited by this paper
• β2-Adrenergic receptor-induced proliferation of human cardiac fibroblasts

  2002cited by this paper
• Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo.

  2001cited by this paper
• In-vivo studies do not support a major functional role for the Gly389Arg beta 1-adrenoceptor polymorphism in humans.

  2001cited by this paper
• The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects.

  2000cited by this paper
• A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure.

  2000cited by this paper
• beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling.

  2000cited by this paper
• A Four Amino Acid Deletion Polymorphism in the Third Intracellular Loop of the Human α2C-Adrenergic Receptor Confers Impaired Coupling to Multiple Effectors*

  2000cited by this paper
• Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release.

  1999cited by this paper
• Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.

  1999cited by this paper
• Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group.

  1999cited by this paper
• Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay.

  1999cited by this paper
• A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor*

  1999cited by this paper
• Adrenergic and muscarinic receptors in the human heart.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Coding block and 5 leader cistron polymorphisms of the beta2-adrenergic receptor.

  1999cited by this paper
• Characterization of a Unique Genetic Variant in the β1-adrenoceptor Gene and Evaluation of its Role in Idiopathic Dilated Cardiomyopathy

  1999cited by this paper
• Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature.

  1998cited by this paper
• Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway.

  1998cited by this paper
• The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease.

  1997cited by this paper
• Plaque Disruption and Coronary Thrombosis: New Insight into Pathogenesis and Prevention

  1997cited by this paper
• Role of catecholamines in platelet function: pathophysiological and clinical significance

  1996cited by this paper
• Mechanism of catecholamine-induced proliferation of vascular smooth muscle cells.

  1996cited by this paper
• Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte

  1992cited by this paper
• Experimental sympathetic activation causes endothelial injury in the rabbit thoracic aorta via beta 1-adrenoceptor activation.

  1990cited by this paper
• An evaluation of the

  1982cited by this paper

• β1- and β2-adrenergic Receptor Haplotypes Regulate Therapeutic Responses to Placebo and the Biased Ligand β-blocker Bucindolol

  2025cites this paper
• Structural and Functional Impact of Adrenoceptor Beta-1 Gene Polymorphism in Patients with Hypertrophic Cardiomyopathy and Response to Beta-Blocker Therapy

  2024cites this paper
• Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults

  2024cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy

  2024cites this paper
• Risk Assessment and Personalized Treatment Options in Inherited Dilated Cardiomyopathies: A Narrative Review

  2024cites this paper
• Cardiovascular precision medicine – A pharmacogenomic perspective

  2023cites this paper
• Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome.

  2023cites this paper
• Pharmacogenomics of adrenergic receptors from bench to bedside: Potential clinical implications in critical care

  2022cites this paper
• Genetics of Anthracycline-Associated Cardiotoxicity

  2022cites this paper
• Genetic Polymorphisms in ADRB2 and ADRB1 Are Associated with Differential Survival in Heart Failure Patients Taking β-Blockers

  2021cites this paper
• Pharmacogenetic polymorphisms affecting bisoprolol response.

  2021cites this paper
• Pharmacogenetics to guide cardiovascular drug therapy

  2021cites this paper
• МЕЖЭТНИЧЕСКИЕ АССОЦИАЦИИ ПОВЫШЕННОЙ ЧАСТОТЫ СЕРДЕЧНЫХ СОКРАЩЕНИЙ, КАК ФАКТОРА СЕРДЕЧНО- СОСУДИСТОГО РИСКА. ЧАСТЬ 2: ГЕНЕТИЧЕСКИЕ МАРКЕРЫ

  2021cites this paper
• Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

  2021cites this paper
• Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers

  2021cites this paper
• Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure

  2020cites this paper
• Adrenergic Receptor Signaling in Heart Failure

  2020cites this paper
• Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.

  2020cites this paper
• Pharmacogenetic factors affecting β-blocker metabolism and response

  2020influential citation
• Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure

  2019cites this paper
• The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5).

  2019cites this paper
• GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population.

  2019cites this paper
• Pharmacogenomics in Hypertension: Where We Stand Today

  2019cites this paper
• Precision Medicine for Heart Failure: Back to the Future.

  2019cites this paper
• Genetics of dilated cardiomyopathy: practical implications for heart failure management

  2019cites this paper
• Adrenergic Polymorphisms and Survival in African Americans With Heart Failure: Results From A-HeFT.

  2019cites this paper
• Challenges and Future in Precision Cardiovascular Medicine

  2019cites this paper
• Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment

  2018cites this paper
• Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena

  2018cites this paper
• Association of Arg389Gly β1-adrenergic receptor polymorphism with effective dose of β blocker in congestive heart failure among Chinese Han population

  2018cites this paper
• Dose Response of &bgr;-Blockers in Adrenergic Receptor Polymorphism Genotypes

  2018cites this paper
• A genotype‐directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC‐AF trial

  2017cites this paper
• Genetics and genomics of dilated cardiomyopathy and systolic heart failure

  2017cites this paper
• Pharmacogenomics of heart failure: a systematic review.

  2016cites this paper
• Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study

  2016cites this paper
• Pharmacological interventions for heart failure in people with chronic kidney disease.

  2016cites this paper
• A Physiologic Approach to the Pharmacogenomics of Hypertension.

  2016cites this paper
• Association between Beta1‐Adrenergic Receptor Polymorphism and Risk of ICD Shock in Heart Failure Patients

  2016cites this paper
• Practical Pharmacogenomic Approaches to Heart Failure Therapeutics

  2016cites this paper
• Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study.

  2016cites this paper
• The Role of Neurohumoral Activation in Cardiac Fibrosis and Heart Failure

  2015cites this paper
• Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure

  2015cites this paper
• The future of pharmacogenetics in the treatment of heart failure.

  2015cites this paper
• Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine

  2015cites this paper
• Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice.

  2015cites this paper
• Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure

  2015influential citation
• Beta Adrenergic Receptors

  2015cites this paper
• Race, common genetic variation, and therapeutic response disparities in heart failure.

  2014cites this paper
• Genetics and Heart Failure: A Concise Guide for the Clinician

  2014cites this paper
• Systems pharmacology-based approach for dissecting the addition and subtraction theory of traditional Chinese medicine: An example using Xiao-Chaihu-Decoction and Da-Chaihu-Decoction

  2014cites this paper
• Polymorphic Variants of Adrenoceptors: Pharmacology, Physiology, and Role in Disease

  2014cites this paper
• Pharmacogenomics in Heart Failure: Where Are We Now and How Can We Reach Clinical Application?

  2014cites this paper
• Heart failure patients with B1-adrenoreceptor polymorphisms have augmented carvedilol response as detected by cardiac I123-MIBG scintigraphy.

  2014cites this paper
• Alpha-1–Adrenergic Receptors in Heart Failure: The Adaptive Arm of the Cardiac Response to Chronic Catecholamine Stimulation

  2014cites this paper
• Genetics of Heart Failure

  2014cites this paper
• An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure: A MERIT‐HF Substudy

  2014cites this paper
• Potential applications of pharmacogenomics to heart failure therapies.

  2014cites this paper
• A systematic review on pharmacogenetics in cardiovascular disease Is it ready for clinical application ?

  2013cites this paper
• Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias With Bucindolol in Patients With Chronic Heart Failure

  2013cites this paper
• Pharmacogenomics and Cardiovascular Disease

  2013cites this paper
• Pharmacogenetics of ò1-Adrenergic Receptor Blockers in Heart FailureTherapy: A Systematic Review

  2013influential citation
• Adrenergic Nervous System in Heart Failure: Pathophysiology and Therapy

  2013cites this paper
• Genetic Prediction of Heart Failure Incidence, Prognosis and Beta-blocker Response

  2013cites this paper
• Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism.

  2013cites this paper
• State of play of pharmacogenetics and personalized medicine in heart failure.

  2013cites this paper
• Genetic and pharmacogenetic determinants of cardiovascular disease

  2013cites this paper
• Expanding Role of Pharmacogenomics in the Management of Cardiovascular Disorders

  2013cites this paper
• β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity.

  2013cites this paper
• Pharmacogenetics of β1-Adrenergic Receptor Blockers in Heart Failure Therapy: A Systematic Review

  2013influential citation
• Pharmacogenetic Advances in Cardiovascular Medicine: Relevance to Personalized Medicine

  2013cites this paper
• Association between adrenergic receptor genotypes and beta‐blocker dose in heart failure patients: analysis from the HF‐ACTION DNA substudy

  2013cites this paper
• Polimorfizm wybranych genów oraz ich wpływ na występowanie zaburzeń rytmu i rokowanie w przewlekłej niewydolności serca

  2013cites this paper
• Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation

  2013cites this paper
• Pharmacogenomics and heart failure in congenital heart disease.

  2013cites this paper
• Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms

  2012cites this paper
• Pharmacogenetic targeting of drugs for heart failure.

  2012cites this paper
• β1 Adrenergic Receptor Polymorphisms and Heart Failure: A Meta-Analysis on Susceptibility, Response to β-Blocker Therapy and Prognosis

  2012cites this paper
• Chapter 45 – Adrenergic Receptor Polymorphisms in Heart Failure

  2012cites this paper
• A Case for Pharmacogenomics in Management of Cardiac Arrhythmias

  2012cites this paper
• Effect of the Arg389Gly β1‐adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype‐dependent response to metoprolol treatment

  2012cites this paper
• The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure

  2012influential citation
• Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges

  2012cites this paper
• Pharmacogenetics and anaesthesia: the value of genetic profiling

  2012influential citation
• A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation.

  2012cites this paper
• Pharmacogenetics of β-Blockers

  2012cites this paper
• Clinical application of cardiovascular pharmacogenetics.

  2012cites this paper
• Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.

  2012cites this paper
• Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.

  2011cites this paper
• Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background

  2011cites this paper
• β(1)-Adrenergic receptor gene polymorphisms and the acute response to atenolol in healthy young Japanese subjects.

  2011cites this paper
• Future of personalized pharmacotherapy in chronic heart failure patients.

  2011cites this paper
• Chapter 42 – Pharmacogenomics and Pharmacogenetics in Heart Failure

  2011cites this paper
• ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee.

  2011cites this paper
• Pharmacogenetics in heart failure trials.

  2011cites this paper
• Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure

  2011cites this paper
• Heart Failure Pharmacogenetics: Past, Present, and Future

  2011cites this paper
• Chapter 46 – Antagonism of the Sympathetic Nervous System in Heart Failure

  2011cites this paper
• Controversies in cardiovascular medicine A systematic review on pharmacogenetics in cardiovascular disease : is it ready for clinical application ?

  2011cites this paper
• The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart

  2011cites this paper
• Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology.

  2011cites this paper